Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 11/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080004 | 0.76 | SIGMAR1 (0.41) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL4560566 | 0.71 | ADRB1 (0.38) | HTTALDH1A1HTR6KMT2ACHRM2 | |
| SCHEMBL16842652 | 0.67 | HSD11B1 (0.43) | HTTHTR6KMT2ASMN1; SMN2 | |
| SCHEMBL18284663 | 0.66 | SIGMAR1 (0.45) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL1079999 | 0.66 | ALDH1A1 (0.47) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL3256689 | 0.65 | SIGMAR1 (0.41) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL1088228 | 0.65 | SIGMAR1 (0.39) | KMT2ASIGMAR1POLB | |
| SCHEMBL4559299 | 0.64 | OPRD1 (0.39) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL5139721 | 0.64 | OPRD1 (0.49) | HTTALDH1A1KMT2ACHRM2CHRM1 | |
| SCHEMBL3256684 | 0.63 | SIGMAR1 (0.41) | HTTALDH1A1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HTT 1010/4885ALDH1A1 532/4885HTR6 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.